Table 3 Hazard ratios (HRs) and 95% confidential intervals (CIs) for disease-free survival and overall survival in all patients.

From: Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy

Variables

Disease-free survival

Overall survival

Univariate

Multivariate

Univariate

Multivariate

HRs (95% CIs)

P-value

HRs (95% CIs)

P-value

HRs (95% CIs)

P-value

HRs (95% CIs)

P-value

Age

0.988 (0.972–1,003)

0.120

0.989 (0.974–1.005)

0.179

1.017 (0.993–1.042)

0.160

1.013 (0.989–1.038)

0.294

NLR

< 2.74

Ref

 

Ref

 

Ref

 

Ref

 

≥ 2.74

2.604 (1.927–3.518)

 < 0.001

2.298 (1.691–3.124)

 < 0.001

2.235 (1.391–3.591)

0.001

1.905 (1.167–3.108)

0.010

cT stage

 

0.042

 

0.247

 

0.108

 

0.216

1

Ref

 

Ref

 

Ref

 

Ref

 

2

1.093 (0.701–1.702)

0.696

0.996 (0.634–1.565)

0.986

0.933 (0.479–1.818)

0.839

0.767 (0.389–1.513)

0.444

3

1.687 (1.014–2.807)

0.044

1.354 (0.805–2.276)

0.253

1.683 (0.793–3.573)

0.175

1.254 (0.582–2.703)

0.564

cN stage

Negative

Ref

 

Ref

 

Ref

 

Ref

 

Positive

1.706 (1.003–2.900)

0.049

1.752 (1.014–3.027)

0.044

5.037 (1.232–20.587)

0.024

5.302 (1.279–21.986)

0.022

ER

Positive

Ref

 

Ref

 

Ref

 

Ref

 

Negative

1.642 (1.217–2.215)

0.001

2.197 (1.375–3.511)

0.001

3.856 (2.310–6.435)

 < 0.001

5.457 (2.463–12.092)

 < 0.001

PR

Positive

Ref

 

Ref

 

Ref

 

Ref

 

Negative

1.323 (0.976–1.794)

0.071

1.034 (0.649–1.648)

0.889

2.334 (1.389–3.923)

0.001

0.930 (0.422–2.048)

0.857

pCR

Yes

Ref

 

Ref

 

Ref

 

Ref

 

No

3.658 (2.034–6.579)

 < 0.001

4.553 (2.483–8.348)

 < 0.001

2.765 (1.197–6.387)

0.017

4.020 (1.695–9.535)

0.002

Regimen

 

0.033

 

0.723

 

0.110

 

0.914

AC-T

Ref

 

Ref

 

Ref

 

Ref

 

AC

1.307 (0.574–2.975)

0.523

1.252 (0.546–2.868)

0.596

1.132 (0.274–4.679)

0.864

0.920 (0.219–3.866)

0.910

AT

1.625 (1.134–2.328)

0.008

1.189 (0.822–1.721)

0.357

1.922 (1.133–3.260)

0.015

1.189 (0.681–2.075)

0.543

Others

1.736 (0.933–3.231)

0.082

1.262 (0.672–2.373)

0.469

1.524 (0.545–4.259)

0.422

0.882 (0.308–2.529)

0.815

  1. NLR neutrophil to lymphocyte ratio, cT clinical T stage, cN clinical N stage, ER estrogen receptor, PR progesterone receptor, pCR pathologic complete response, AC-T doxorubicin and cyclophosphamide followed by taxane, AC doxorubicin and cyclophosphamide, AT doxorubicin and taxane.
  2. *Others: cyclophosphamide, doxorubicin, 5-fluorouracil (CAF); cyclophosphamide, methotrexate, 5-fluorouracil (CMF); taxane; taxane plus carboplatin.
Back to article page